Compositions and methods for promoting myocardial and peripheral angiogenesis
View Patent ↗Methods, compositions and devices are disclosed for use in growing new blood vessels to restore or improve blood flow to ischemic tissues and organs of the body. Compositions comprising IGD peptides, particularly GGIGDGG, are able to induce migration in human endothelial cells and promote vessel formation in an in vitro model assay system.
1. The isolated peptide sequence GGIGDGG (SEQ ID NO: 2).
2. An angiogenic composition comprising the isolated peptide sequence GGIGDGG (SEQ ID NO: 2) and at least one angiogenic peptide selected from the group consisting of bone-derived angiogenic proteins (BDAPs), vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, endothelial growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), and tumor necrosis factor-alpha (TNF-α).
3. The angiogenic composition of claim 2 wherein at least one said angiogenic peptide is a recombinant angiogenic peptide.
4. The angiogenic composition of claim 2 wherein said at least one angiogenic peptide is a bone-derived angiogenic protein (BDAP).
5. The angiogenic composition of claim 2 wherein said at least one angiogenic peptide is vascular endothelial cell growth factor (VEGF).
6. The composition of claim 2 , further comprising a pharmacologically acceptable carrier.
7. The composition of claim 6 wherein the pharmacologically acceptable carrier comprises polyvinylpyrrolidinone.
8. The composition of claim 6 wherein the pharmacologically acceptable carrier comprises hydrochloric acid.
9. The composition of claim 6 , wherein the composition further comprises polyvinylpyrrolidinone.
10. The composition of claim 6 , wherein the composition further comprises hydrochloric acid.
11. The composition of claim 2 , wherein the composition is an injectable solution.
12. A composition that is active for promoting cell migration and/or angiogenesis under cell growth promoting conditions, the composition comprising the isolated peptide sequence GGIGDGG (SEQ ID NO: 2) and a matrix material.
13. The composition of claim 12 , further comprising a pharmacologically acceptable carrier.
14. The angiogenic composition of claim 12 , further comprising at least one angiogenic peptide selected from the group consisting of bone-derived angiogenic proteins (BDAPs), vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, endothelial growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), and tumor necrosis factor-alpha (TNF-α).
15. The angiogenic composition of claim 14 wherein said at least one angiogenic peptide is a bone-derived angiogenic protein (BDAP).
16. The angiogenic composition of claim 14 wherein said at least one angiogenic peptide is vascular endothelial cell growth factor (VEGF).
17. The composition of claim 12 , further comprising a pharmacologically acceptable carrier.
18. The composition of claim 17 wherein the pharmacologically acceptable carrier comprises polyvinylpyrrolidinone.
19. The composition of claim 17 wherein the pharmacologically acceptable carrier comprises hydrochloric acid.
20. The composition of claim 12 , wherein the composition is an injectable solution.
21. The composition of claim 20 , wherein the composition further comprises polyvinylpyrrolidinone.
22. The composition of claim 20 , wherein composition further comprises hydrochloric acid.
23. The angiogenic composition of claim 12 wherein said matrix comprises a cell growth promoting matrix.